Management of pulmonary hypertension and right heart failure in the intensive care unit
Related Experiment Video
Updated: Apr 15, 2026

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Jonathan Grinstein1, Mardi Gomberg-Maitland
1Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA, jonathan.grinstein@uchospitals.edu.
Abstract:
Management of acute right ventricular failure, both with and without coexisting pulmonary hypertension, is a common challenge encountered in the intensive care setting. Both right ventricular dysfunction and pulmonary hypertension portend a poor prognosis, regardless of the underlying cause and are associated with significant morbidity and mortality. The right ventricle is embryologically distinct from the left ventricle and has unique morphologic and functional properties. Management of right ventricular failure and pulmonary hypertension in the intensive care setting requires tailored hemodynamic management, pharmacotherapy, and often mechanical circulatory support. Unfortunately, our understanding of the management of right ventricular failure lags behind that of the left ventricle. In this review, we will explore the underlying pathophysiology of the failing right ventricle and pulmonary vasculature in patients with and without pulmonary hypertension and discuss management strategies based on evidence-based studies as well as our current understanding of the underlying physiology.
More Related Videos
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cardiac Catheterization II: Right Heart Catheterization
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

